Shunsuke Ebara

512 total citations
15 papers, 325 citations indexed

About

Shunsuke Ebara is a scholar working on Molecular Biology, Oncology and Pathology and Forensic Medicine. According to data from OpenAlex, Shunsuke Ebara has authored 15 papers receiving a total of 325 indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Molecular Biology, 7 papers in Oncology and 2 papers in Pathology and Forensic Medicine. Recurrent topics in Shunsuke Ebara's work include Cancer-related Molecular Pathways (5 papers), RNA modifications and cancer (4 papers) and Ubiquitin and proteasome pathways (4 papers). Shunsuke Ebara is often cited by papers focused on Cancer-related Molecular Pathways (5 papers), RNA modifications and cancer (4 papers) and Ubiquitin and proteasome pathways (4 papers). Shunsuke Ebara collaborates with scholars based in Japan and United States. Shunsuke Ebara's co-authors include Takahito Hara, Ayumi Ando, Yoshinori Satomi, Saomi Murai, Akito Nakamura, Megumi Hirayama, Akito Hata, Jan‐Fang Cheng, S G Fischer and Anthony Ratcliffe and has published in prestigious journals such as Proceedings of the National Academy of Sciences, PLoS ONE and Cancer Research.

In The Last Decade

Shunsuke Ebara

11 papers receiving 323 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Shunsuke Ebara Japan	7	208	88	68	65	31	15	325
Ryan H. Livengood United States	8	172 0.8×	53 0.6×	83 1.2×	68 1.0×	33 1.1×	17	301
Hui Rao China	10	299 1.4×	125 1.4×	103 1.5×	77 1.2×	36 1.2×	19	439
Caihong Yang China	12	241 1.2×	107 1.2×	68 1.0×	45 0.7×	60 1.9×	19	348
Zhuoying Lin China	9	215 1.0×	91 1.0×	77 1.1×	32 0.5×	58 1.9×	16	362
Ryan Traynor United Kingdom	6	256 1.2×	33 0.4×	62 0.9×	38 0.6×	21 0.7×	7	352
Yuniel Fernández‐Marrero Switzerland	13	203 1.0×	54 0.6×	59 0.9×	46 0.7×	13 0.4×	22	389
Zhifa Cao China	7	191 0.9×	103 1.2×	89 1.3×	61 0.9×	70 2.3×	11	380
Shuzhou Chu China	13	288 1.4×	92 1.0×	92 1.4×	45 0.7×	53 1.7×	19	403
Xian-Zi Yang China	8	225 1.1×	95 1.1×	95 1.4×	30 0.5×	23 0.7×	8	320

Countries citing papers authored by Shunsuke Ebara

Since Specialization

Citations

This map shows the geographic impact of Shunsuke Ebara's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Shunsuke Ebara with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Shunsuke Ebara more than expected).

Fields of papers citing papers by Shunsuke Ebara

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Shunsuke Ebara. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Shunsuke Ebara. The network helps show where Shunsuke Ebara may publish in the future.

Co-authorship network of co-authors of Shunsuke Ebara

This figure shows the co-authorship network connecting the top 25 collaborators of Shunsuke Ebara. A scholar is included among the top collaborators of Shunsuke Ebara based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Shunsuke Ebara. Shunsuke Ebara is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

15 of 15 papers shown

Inoue, Yasumichi, Koki Hikami, Shunsuke Ebara, et al.. (2025). Abstract 1745: Combining HRI/PERK/GCN2 inhibitor CRD-799 with proteasome inhibitors provides a novel approach to overcoming resistance in multiple myeloma treatment. Cancer Research. 85(8_Supplement_1). 1745–1745.

Tarumoto, Yusuke, S. M. Didar-Ul Islam, Shunsuke Ebara, et al.. (2025). Abstract 1636: Novel CDK12/13 inhibitor CTX-439 downregulates MCL1 via transcriptional mRNA read-through and synergistically acts with BCL-XL inhibitors for cancer therapy. Cancer Research. 85(8_Supplement_1). 1636–1636.

Ebara, Shunsuke, Koji Yamamoto, Kôzô Hayashi, et al.. (2024). Phosphorylation Dynamics and Kinase Interaction in mRNA Transcription-Associated Kinases: Autophosphorylation of CDK12 and its Modulation by CDK7 and CDK9. 7(5). 170–177.

Ebara, Shunsuke, et al.. (2024). Interaction of CDK12 with NXF1 is a new node for the linking mechanism between transcription and transportation of mRNA. Biochemical and Biophysical Research Communications. 735. 150608–150608.

Inoue, Yasumichi, Koki Hikami, Shunsuke Ebara, et al.. (2024). Abstract 1233: Novel inhibitor targeting triple integrated stress response kinase HRI, PERK, and GCN2 provides new insights into overcoming resistance to proteasome inhibitors in multiple myeloma. Cancer Research. 84(6_Supplement). 1233–1233. 1 indexed citations

Ebara, Shunsuke, Akio Mizutani, Koji Yamamoto, et al.. (2024). Abstract 3301: Translational research of CDK12/13 inhibitor, CTX-439, informing clinical trial strategy. Cancer Research. 84(6_Supplement). 3301–3301. 1 indexed citations

Mizutani, Akio, et al.. (2022). Abstract 5485: Discovery and preclinical evaluation of a novel highly selective and potent CDK12 inhibitor. Cancer Research. 82(12_Supplement). 5485–5485. 1 indexed citations

Murai, Aiko, Shunsuke Ebara, Satoshi Sasaki, et al.. (2020). Synergistic apoptotic effects in cancer cells by the combination of CLK and Bcl-2 family inhibitors. PLoS ONE. 15(10). e0240718–e0240718. 15 indexed citations

Nakamura, Akito, Daisuke Nakata, Saomi Murai, et al.. (2018). CDK8/19 inhibition induces premature G1/S transition and ATR-dependent cell death in prostate cancer cells. Oncotarget. 9(17). 13474–13487. 31 indexed citations

10.

Nakamura, Akito, Tadahiro Nambu, Shunsuke Ebara, et al.. (2018). Inhibition of GCN2 sensitizes ASNS-low cancer cells to asparaginase by disrupting the amino acid response. Proceedings of the National Academy of Sciences. 115(33). E7776–E7785. 110 indexed citations

11.

Baba, Yuji, Toshiya Tamura, Yoshihiko Satoh, et al.. (2017). Panitumumab interaction withTAS‐102 leads to combinational anticancer effects via blocking ofEGFR‐mediated tumor response to trifluridine. Molecular Oncology. 11(8). 1065–1077. 18 indexed citations

12.

Murai, Saomi, Ayumi Ando, Shunsuke Ebara, et al.. (2017). Inhibition of malic enzyme 1 disrupts cellular metabolism and leads to vulnerability in cancer cells in glucose-restricted conditions. Oncogenesis. 6(5). e329–e329. 63 indexed citations

13.

Kitazawa, Satoshi, Shunsuke Ebara, Ayumi Ando, et al.. (2017). Succinate dehydrogenase B-deficient cancer cells are highly sensitive to bromodomain and extra-terminal inhibitors. Oncotarget. 8(17). 28922–28938. 26 indexed citations

14.

Ebara, Shunsuke, Yuki Sakamoto, Kenta Iijima, et al.. (2014). Mutations in the FHA-domain of ectopically expressed NBS1 lead to radiosensitization and to no increase in somatic mutation rates via a partial suppression of homologous recombination. Journal of Radiation Research. 55(4). 690–698. 2 indexed citations

15.

Valhmu, Wilmot B., Glyn D. Palmer, Shunsuke Ebara, et al.. (1995). Structure of the human aggrecan gene: exon-intron organization and association with the protein domains. Biochemical Journal. 309(2). 535–542. 57 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact